Your Situationship Is Still in Phase 1. Phase 3 Is Where Things Actually Get Proven.
It is that time of year.
Research Triangle Park turns 67 this year, and it's having one of its biggest stretches yet — Biogen committing another $2 billion to its RTP campus, Eli Lilly expanding a $474 million manufacturing facility, Johnson & Johnson breaking ground on a second North Carolina site. The Triangle is home to seven of the world's top ten clinical research organizations and more life science companies than anywhere else in the country. Everyone in Raleigh either works in this industry or knows ten people who do, which means everyone here also, technically, knows the difference between a Phase 1 trial and a Phase 3 one. Most people just aren't applying that knowledge to their own dating life.
Here's the thing nobody's saying out loud over a flat white in Five Points: your situationship has been running a Phase 1 trial for the better part of a year, and you've been quietly treating the results like they're Phase 3 data.
Raleigh Dating, By the Numbers
The median age in Raleigh is 34-35, with a relatively low 42% marriage rate — well below the national norm.
Raleigh sees roughly 18% new-resident turnover annually, driven heavily by the Triangle's research and tech industries — a constantly refreshing, constantly transient dating pool.
Despite all that, Raleigh ranked a middling 84th out of 182 U.S. cities in a 2025 WalletHub dating-friendliness study, with neighboring Durham landing even lower at 153rd.
The Research Triangle Region is home to more than 675 life science companies, including seven of the top ten global Contract Research Organizations — the industry that, almost single-handedly, invented the modern outsourced clinical trial.
Now let's check the trial design properly.
Protocol: Situationship Phase: Still Phase 1 Investigator: You, treating early data like it's already proven
Phase 1 — "Small Group, Safety Only, Not Designed to Prove Anything Works"
A Phase 1 trial exists to answer one narrow question: is this safe enough to keep testing. It's run on a small group, it's not statistically powered to prove efficacy, and no responsible researcher would ever greenlight a drug off Phase 1 results alone. Most situationships never make it past an equivalent stage — a small, low-stakes sample of good interactions that establishes basic safety (they're not awful, nothing's gone wrong yet) without remotely proving the bigger question anyone actually cares about.
Double-Blind — "Neither Person Knows What's Actually Being Tested"
Good trials are double-blind for a reason: neither the subject nor the administrator knows who's getting the real treatment, which keeps expectation from contaminating the result. A situationship where neither person has said plainly what they're actually hoping this becomes is running an accidental double-blind — except nobody designed it that way on purpose, and unlike a real trial, nobody's planning to unblind the results and find out what actually happened.
Endpoint — "The Thing You're Supposed to Define Before You Start, Not After"
Every legitimate clinical trial has a predefined primary endpoint — a specific, measurable outcome decided in advance, so nobody can quietly move the goalposts once the data starts coming in. Most situationships never define one. There's no agreed-upon measure of what "this worked" would actually look like, which means there's no way to honestly determine, six months in, whether the trial succeeded or just continued.
Phase 3 — "Large-Scale, Real Conditions, the Only Data That Actually Earns Approval"
Phase 3 is where a drug gets tested on thousands of people, across multiple sites, under real-world conditions, specifically because a treatment that looked great on forty people in a controlled setting often performs completely differently at scale. A situationship that's only ever been tested in ideal conditions — good moods, free weekends, nothing actually at stake — hasn't reached Phase 3. It's been Phase 1 for a long time, and Phase 1 was never designed to tell you what you're trying to find out.
Here's what every researcher in RTP already understands and somehow doesn't apply to their own relationships: promising early data is not the same as proof. The industry's entire business model exists because Phase 1 success rates and eventual FDA approval rates are wildly different numbers — most things that look safe and encouraging in a small trial never make it through Phase 3 at all.
Most Raleigh situationships are stuck running an indefinite Phase 1 — genuinely pleasant data, small sample, untested under any real pressure — and calling the fact that nothing's gone wrong yet a sign the bigger trial would succeed too. A good string of dates in Glenwood South or a comfortable few months in North Hills feels like real evidence. It's preliminary. It was never designed to be conclusive.
That's most of what an actual matchmaker does here that an under-powered sample and good vibes cannot — someone outside the protocol, looking honestly at what phase you're actually in, willing to say "this hasn't been tested under real conditions yet" instead of treating early safety data as proof of efficacy.
The Triangle runs on rigorous trial design for a reason — it's the only way anything actually gets proven. The real question is whether your situationship has an actual endpoint defined at all, or whether you've just been running Phase 1 indefinitely and calling the absence of bad results a win.
Sources
Biogen's $2 billion RTP expansion; Eli Lilly's $474M manufacturing facility; J&J's second NC site; RTP's 675+ life science companies and seven of the top ten global CROs — Labiotech.eu, Healthcare Brew, and WorkInTheTriangle.com, all 2025–2026.
Raleigh median age 34–35, 42% marriage rate, 18% new-resident inflow — Photomaxxer's Raleigh dating apps guide, 2026.
Raleigh ranked 84th of 182 cities for dating-friendliness, Durham at 153rd — WalletHub 2025 study, via CBS17/WNCN, December 2025.
Raleigh-Cary population grew 10.2% to 1.6M, 2020–2024 — Healthcare Brew